SOUTH BOSTON, Va., March 30, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) has lodged filings with the Securities and Exchange Commission and the Australian Securities Exchange relating to changes in Directors’ and Officer’s ownership in IperionX. A summary of the changes can be found below. Director / OfficerNo. of Securities AcquiredValue / ConsiderationValue / Consideration (US$)1Anastasios ARIMA467,000 Shares12,800 ADSsA$1,493,480.25(Shares) US$299,643.64 (ADSs)US$1,331,78 ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of IperionX Limited ("IperionX†or the "Company†) (NASDAQ: IPX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IPERIONX LIMITED (IPX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On March 13, 2026, IperionX disclosed that its financial report for the. ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of IperionX Limited ("IperionX†or the "Company†) (NASDAQ: IPX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IPERIONX LIMITED (IPX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 13, 2026, IperionX disclos. ...

Core Viewpoint - Law Offices of Howard G. Smith is investigating IperionX Limited for potential violations of federal securities laws, indicating possible legal issues that may affect investors [1] Company Summary - IperionX Limited is listed on NASDAQ under the ticker symbol IPX [1] - The investigation is aimed at protecting the interests of investors who may have suffered losses related to their investments in IperionX [1]

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of IperionX Limited ("IperionX†or the "Company†) (NASDAQ: IPX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IPERIONX LIMITED (IPX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March. ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of IperionX Limited due to significant financial losses and a recent correction of financial statements [1][4]. Group 1: Financial Performance - IperionX reported a net loss of approximately $34.8 million for the first half of fiscal year 2026, compared to a loss of $16.2 million in the same period the previous year [3]. - A typographical error in a prior financial statement overstated certain reported figures by approximately $330 million, leading to a decline in the company's share price following the earnings release and subsequent correction [4]. Group 2: Legal Investigation - Johnson Fistel is investigating whether IperionX complied with federal securities laws in light of the financial losses and the correction of the financial statements [1][4]. - Investors who suffered losses from their investment in IperionX stock are encouraged to join the investigation [2].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating IperionX Limited for potential violations of federal securities laws, particularly concerning financial disclosures made by the company [1]. Company Investigation - The investigation is initiated on behalf of investors who may have incurred losses due to the company's actions [1]. - IperionX disclosed financial report details on March 13, 2026, which are under scrutiny [1].

Financial Performance - For the six months ended December 31, 2025, IperionX reported a loss of $34,768,116, compared to a loss of $16,236,871 for the same period in 2024, representing a 114% increase in losses year-over-year[5] - The company reported a total comprehensive loss of $33,461,270 for the six months ended December 31, 2025, compared to $21,129,105 for the same period in 2024, a 58% increase[5] - The company’s cash flows used in operating activities amounted to $16,702,754 for the six months ended December 31, 2025, compared to $11,748,806 in 2024, a 42% increase[9] - The Group reported net outflows from operating and investing activities of US$(33.1) million for the six months ended December 31, 2025, compared to US$(22.7) million in 2024[18] Research and Development - Research and development costs increased to $10,785,188 in 2025 from $6,809,195 in 2024, reflecting a 58% rise[5] - IperionX's exploration and evaluation expenses increased to $3,298,759 in 2025 from $1,393,608 in 2024, a 137% increase[5] Assets and Equity - Total assets as of December 31, 2025, were $129,156,114, up from $105,034,979 as of June 30, 2024, indicating a 23% increase[6] - The company’s total equity rose to $108,201,890 as of December 31, 2025, from $92,443,999 as of June 30, 2024, reflecting a 17% increase[6] - As of December 31, 2025, total trade and other receivables amounted to US$1,154,337, up from US$823,268 on June 30, 2025[30] - Total trade and other payables increased to US$10,367,158 as of December 31, 2025, compared to US$7,489,397 on June 30, 2025[39] - The carrying amount of property, plant, and equipment increased to US$35,936,076 as of December 31, 2025, from US$25,197,638 on June 30, 2025[33] - The carrying amount of exploration and evaluation assets for the Titan Project rose to US$7,515,238 as of December 31, 2025, from US$6,512,326 on June 30, 2025[36] Shareholder Information - The Company completed the placement of 14 million new fully paid ordinary shares at A$5.00 per share, raising gross proceeds of A$70 million (approximately US$46.0 million) before costs[19] - The company raised gross proceeds of approximately US$46 million by issuing 14,000,000 new fully paid ordinary shares at A$5.00 per share on October 10, 2025[42] - As of December 31, 2025, the company had a closing balance of 336,322,679 ordinary shares issued and outstanding, an increase from 315,846,248 shares as of December 31, 2024[42][44] - The share-based payments reserve increased to US$10,345,002 as of December 31, 2025, up from US$6,469,201 at June 30, 2025[45] - The share-based payments reserve saw a significant reduction in unlisted options, dropping from 12,904,118 to 3,020,839 during the six months ended December 31, 2025[46] Government Funding and Contracts - The Company received US$59.8 million in awards under U.S. government funding programs, with US$55.2 million obligated under contracts as of December 31, 2025[22] - The Company executed a US$12.7 million contract under the U.S. Department of War DPA Title III authorities, matched with US$13.4 million from the Company, totaling US$26.1 million for the Titanium Production Facility in Virginia[23] - The Company was awarded up to US$47.1 million by the U.S. Department of War to strengthen the U.S. Defense Industrial Base, matched with US$49.2 million from the Company, totaling US$96.3 million[25] - The U.S. Department of War obligated a total of US$42.5 million under a US$47.1 million award to support the company's titanium supply chain scale-up[50][51] Operational Developments - The company is focused on developing titanium metal technologies and aims to support advanced industries including aerospace and automotive[11] - IperionX is operating a U.S.-based integrated titanium business to establish a sustainable titanium supply chain[12] - The company received approximately 290 metric tons of high-quality titanium alloy scrap metal from the U.S. Government, equivalent to about 1.5 years' worth of titanium feedstocks at current operating capacity[53] - A prototype purchase order worth US$0.3 million was received from American Rheinmetall for producing 700 lightweight titanium components for U.S. Army systems, with potential for larger agreements[54] Subsidiaries and Future Outlook - The company has 100% equity interest in its subsidiaries, including Hyperion Metals and IperionX Critical Minerals LLC, as of December 31, 2025[47] - No significant matters have arisen since December 31, 2025, that could affect the company's operations or financial results in subsequent years[55]

Core Viewpoint - IperionX Limited reported a significant loss in the first half of fiscal 2026, leading to a notable decline in its stock price, indicating potential concerns about its financial health and future profitability [1][2]. Financial Performance - IperionX reported a loss of $0.10 per share for the first half of fiscal 2026, with no revenue generated during this period [1][2]. - The company incurred total expenses of $34.8 million, which included $10.8 million on research and development and $3.3 million on exploration work [2]. - The loss of $0.10 per share is worse than the previous year's loss of $0.06 per share [2]. Cash Position - IperionX holds $65.8 million in cash and equivalents, which is sufficient to sustain operations for another year despite the incurred capital expenditures of $31.1 million [3]. Future Outlook - Analysts forecast that IperionX will end the fiscal year with a loss of $0.07 per share, which is an improvement compared to the current loss [4]. - There is an expectation that IperionX will achieve profitability in fiscal 2027, although the projected profit is only $0.06 per share [4]. Investment Sentiment - The current stock price of $41 is considered expensive relative to the forecasted profit, leading to a recommendation to sell [5]. - IperionX was not included in a list of top stock recommendations by a prominent investment advisory team, suggesting a lack of confidence in its near-term investment potential [7].

Core Insights - The U.S. rare earth landscape is heavily reliant on upstream activities, while REalloys operates firmly in the downstream sector, providing essential materials for defense applications [1][4][5] - Heavy rare earths, particularly dysprosium and terbium, are critical for modern military systems, including precision-guided missiles [2][3] Company Overview - REalloys is the only North American company producing defense-grade heavy rare earth metals and alloys, with a facility in Euclid, Ohio [4][5] - The company has secured long-term feedstock agreements from North America, Kazakhstan, Greenland, and Brazil, processing materials domestically to meet U.S. Department of Defense specifications [4][7][9] Production Capacity and Expansion - REalloys is expanding its facility to increase heavy rare earth processing capacity by 300% and light rare earth (NdPr) capacity by 50%, with production expected to begin in early 2027 [8] - The facility aims to produce up to 30 tonnes of dysprosium oxide, 15 tonnes of terbium oxide, and 400 tonnes of high-purity NdPr metal annually, increasing to 600 tonnes post-expansion [8] Strategic Importance - The U.S. military's reliance on REalloys for rare earth metals is crucial as sourcing rules change in 2027, making Chinese materials ineligible [3][4] - The ability to produce magnet materials domestically at scale is vital for U.S. military readiness and industrial capacity [5][6] Industry Context - The Center for Strategic and International Studies (CSIS) identifies rare-earth metallization and alloying as the most challenging capabilities to rebuild outside China, emphasizing the importance of REalloys' operational facility [16][17] - The U.S. is under pressure to rebuild its rare-earth supply chain amid strategic competition with China, highlighting the urgency of domestic production capabilities [14][19]